ப்ரிந்‌ஸிபிய சனோஃபி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ரிந்‌ஸிபிய சனோஃபி. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ரிந்‌ஸிபிய சனோஃபி Today - Breaking & Trending Today

Sanofi starts off 'pipeline-in-a-product' rilzabrutinib in rare skin disease, but eyes bigger prize


Apr 23, 2021 10:00am
Sanofi picked up the BTK inhibitor rilzabrutinib in the $3.7 billion acquisition of Principia Biopharma in 2020, a unit now known as Principia Sanofi.
Sanofi has big dreams for rilzabrutinib in diseases ranging from atopic dermatitis to asthma, but up first for the potential blockbuster is a phase 2 read out for the rare skin disease pemphigus vulgaris.
Rilzabrutinib was found to reduce steroid use and improve the quality of life in patients with the disorder, which can cause painful skin blisters and infections, in a midstage clinical trial called Believe. Sanofi presented the data during a late-breaking abstract at the American Academy of Dermatology (AAD) meeting April 23. The drug managed to reduce the severity of lesions at the 12 week and 24 week mark and led to a reduction in steroid use at 12 weeks. ....

United States , Principia Sanofi , Principia Biopharma , Naimish Patel , Naimish Patel Sanofi , American Academy Of Dermatology , International Pemphigus , Pemphigoid Foundation , American Academy , Principia Biopharma , Atopic Dermatitis , Clinical Research , Autoimmune Disease , Drug Development , ஒன்றுபட்டது மாநிலங்களில் , ப்ரிந்‌ஸிபிய சனோஃபி , நைமிஷ படேல் , அமெரிக்கன் கலைக்கழகம் ஆஃப் தோல் நோய் , அமெரிக்கன் கலைக்கழகம் , கம்பளி வளர்ச்சி ,